Recent Advances in Rapid Antimicrobial Susceptibility Testing.
Journal
Clinical chemistry
ISSN: 1530-8561
Titre abrégé: Clin Chem
Pays: England
ID NLM: 9421549
Informations de publication
Date de publication:
30 12 2021
30 12 2021
Historique:
received:
29
06
2021
accepted:
17
09
2021
entrez:
30
12
2021
pubmed:
31
12
2021
medline:
14
4
2022
Statut:
ppublish
Résumé
Antimicrobial susceptibility testing (AST) is classically performed using growth-based techniques that essentially require viable bacterial matter to become visible to the naked eye or a sophisticated densitometer. Technologies based on the measurement of bacterial density in suspension have evolved marginally in accuracy and rapidity over the 20th century, but assays expanded for new combinations of bacteria and antimicrobials have been automated, and made amenable to high-throughput turn-around. Over the past 25 years, elevated AST rapidity has been provided by nucleic acid-mediated amplification technologies, proteomic and other "omic" methodologies, and the use of next-generation sequencing. In rare cases, AST at the level of single-cell visualization was developed. This has not yet led to major changes in routine high-throughput clinical microbiological detection of antimicrobial resistance. We here present a review of the new generation of methods and describe what is still urgently needed for their implementation in day-to-day management of the treatment of infectious diseases.
Sections du résumé
BACKGROUND
Antimicrobial susceptibility testing (AST) is classically performed using growth-based techniques that essentially require viable bacterial matter to become visible to the naked eye or a sophisticated densitometer.
CONTENT
Technologies based on the measurement of bacterial density in suspension have evolved marginally in accuracy and rapidity over the 20th century, but assays expanded for new combinations of bacteria and antimicrobials have been automated, and made amenable to high-throughput turn-around. Over the past 25 years, elevated AST rapidity has been provided by nucleic acid-mediated amplification technologies, proteomic and other "omic" methodologies, and the use of next-generation sequencing. In rare cases, AST at the level of single-cell visualization was developed. This has not yet led to major changes in routine high-throughput clinical microbiological detection of antimicrobial resistance.
SUMMARY
We here present a review of the new generation of methods and describe what is still urgently needed for their implementation in day-to-day management of the treatment of infectious diseases.
Identifiants
pubmed: 34969098
pii: 6490217
doi: 10.1093/clinchem/hvab207
doi:
Substances chimiques
Anti-Bacterial Agents
0
Anti-Infective Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
91-98Subventions
Organisme : bioMérieux
Organisme : European Union's Horizon 2020 Research and Innovation Program
Organisme : Bacterial Adhesin Network Training (ViBrANT)
ID : 765042
Organisme : Accelerate Diagnostics, OpGen Inc
Organisme : BD Diagnostics
Organisme : bioMerieux, Inc.
Organisme : Affinity Biosensors
Organisme : Hardy Diagnostics, and personal fees from Roche Diagnostics
Organisme : Shionogi Inc.
Organisme : GeneCapture
Informations de copyright
© American Association for Clinical Chemistry 2021. All rights reserved. For permissions, please email: journals.permissions@oup.com.